---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-122342"
form_type: "8-K"
ticker: "TNYA"
cik: "0001858848"
company_name: "Tenaya Therapeutics, Inc."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:49:49.456298+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tenaya Therapeutics reports Q3 net loss of $25.6M; DSMB clears dose escalation for TN-201 gene therapy

## Summary
- Net loss of $25.6M ($0.30 per share) vs $29.1M ($0.39) in Q3 2023.
- Cash and investments $79.5M; runway expected into H2 2025.
- DSMB recommended dose escalation to 6E13 vg/kg for TN-201 in MyPEAK-1; initial Cohort 1 data expected Dec 2024.
- Expanded MyPEAK-1 eligibility to include obstructive HCM patients and those without ICDs; baseline biopsy added.
- Entered $45M undrawn credit facility with Silicon Valley Bank in August 2024.

## SEC filing metadata
- accession: 0000950170-24-122342
- form_type: 8-K
- ticker: TNYA
- cik: 0001858848
- company_name: Tenaya Therapeutics, Inc.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858848/000095017024122342/0000950170-24-122342-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858848/000095017024122342/tnya-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-122342
- JSON: https://secwatch.observer/filing/0000950170-24-122342.json
- Plain text: https://secwatch.observer/filing/0000950170-24-122342.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.